Cosamin DS Double Strength Joint Care

#1 Orthopedic Surgeon & Rheumatologist Recommended

Cosamin DS Double StrengthHow Cosamin DS Double Strength Joint Care ®Works

Cartilage is composed of cells (chondrocytes), and cartilage matrix (collagen and proteoglycans containing chondroitin sulfate). Cartilage breaks down when the matrix cannot be replenished completely. Cartilage cells constantly replace old and damaged matrix with newcomponents. As one ages, or if cartilage is damaged, cartilage cells die off and are not replaced. With the loss of cartilage cells, there is also a loss of the healthy cartilage matrix. This adversely affects adjacent cartilage cells, thus beginning the downward cycle of joint deterioration. Enzymes released by deteriorating cartilage cells and the cells that line the fibrous joint capsule continue to break down the old and damaged matrix structures. The remaining cartilage cells, stressed by their deteriorating environment, cannot keep pace by producing new matrix, as they once did.

Cosamin DS Double Strength Joint Care ® is a combination of FCHG49® glucosamine hydrochloride and the specific TRH122 ® low molecular weight (LMW) chondroitin sulfate. These exclusive ingredients in CosaminDS work together to refresh stressed cartilage cells and maximize matrix production.

The two main ingredients in CosaminDS, chondroitin sulfate and glucosamine hydrochloride, stimulate cartilage cells to increase production of cartilage matrix materials. Glucosamine also enhances the capacity of this unique chondroitin sulfate to inhibit the enzymes breaking down the cartilage matrix, restoring a balance and healthier state of the joint. This exclusive formulation found only in CosaminDS can slow this cycle making you feel more comfortable.

REFERENCES

Homandberg GA, Guo D, Ray LM, et al. Mixtures of glucosamine and chondroitin sulfate reverse fibronectin fragment mediated damage to cartilage more effectively than either agent alone.

Osteoarthritis Cartilage

2006;14:793-806.

 

Adebowale A, Du J, Liang Z, et al. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs.

Biopharm Drug Dispos

2002;23:217-225.

 

Chan PS, Caron JP, Orth MW. Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants.

Am J Vet Res

2005;66:1870-1876.

 

Chan PS, Caron JP, Rosa GJM, et al. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants.

Osteoarthritis Cartilage

2005;13:387-394.

 

Dechant JE, Baxter GM, Frisbie DD, et al. Effects of glucosamine hydrochloride and chondroitin sulphate, alone and in combination, on normal and interleukin-1 conditioned equine articular cartilage explant metabolism.

Equine Vet J

2005;37:227-231.

 

Lippiello L, Woodward J, Karpman R, et al. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate.

Clin Orthop Relat Res

2000;381:229-240.

 

McNamara PS, Barr SC, Erb HN, et al. Hematologic, hemostatic, and biochemical effects in cats receiving an oral chondroprotective agent for thirty days.

Vet Therapeutics

2000;1:108-117.

 

McNamara PS, Barr SC, Erb HN. Hematologic, hemostatic, and biochemical effects in dogs receiving an oral chondroprotective agent for thirty days.

Am J Vet Res

1996;57:1390-1394.

 

Orth MW, Peters TL, Hawkins JN. Inhibition of articular cartilage degradation by glucosamine-HCl and chondroitin sulphate.

Equine Vet J Suppl

2002:224-229.

 

Sauve F, Paradis M, Refsal KR, et al. Effects of oral administration of meloxicam, carprofen, and a nutraceutical on thyroid function in dogs with osteoarthritis.

Can Vet J

2003;44:474-479.

 

Chan PS, Caron JP, Orth MW. Effects of glucosamine and chondroitin sulphate on bovine cartilage explants under long-term cartilage conditions.

Am J Vet Res

2007;68:709-715.

 

Chan PS, Caron JP, Orth MW. Short-term gene expression changes in cartilage explants stimulated with interleukin 1-beta plus glucosamine and chondroitin sulfate.

J Rheumatol

2006;33:1329-1340.

 

Das AK, Hammad TA. Efficacy of a combination of FCHG49® glucosamine hydrochloride, TRH122® low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis.

Osteoarthritis Cartilage

2000;8:343-350.

 

Leffler CT, Philippi AF, Leffler SG, et al. Glucosamine, chondroitin and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study.

Mil Med

1999;164:85-91.

 

Scroggie DA, Albright A, Harris MD. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus.

Arch Intern Med

2003;163:1587-1590.

 

van Blitterswijk WJ, van de Nes JCM, Wuisman PIJM. Glucosamine and chondroitin sulfate supplementation to treat symptomatic disc degeneration: biochemical rationale and case report.

BMC Complement Altern Med

2003;3:2.

 

Schenck RC, Clare DJ, Gilley JS, et al. Role of a glucosamine/chondroitin sulfate formula in treatment of an osteochondral impaction injury in a collegiate basketball player.

Ortho Tech Rev

2000;2:12-15.

 

Williams A, Gillis A, McKenzie C, et al.Glycosaminoglycan distribution in cartilage as determined by delayed gadolinium-enhanced MRI of cartilage (dGEMRIC): potential clinical applications.

AJR

2004;182:167-172.

 

Lippiello L, Saiz P. Glucosamine and chondroitin sulfate: biological response modifiers of chondrocytes under simulated conditions of joint stress.

Osteoarthritis Cartilage

2003;11:335-342.

 

Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate and the two in combination for painful knee osteoarthritis.

N Engl J Med

2006;354:795-808.

 

Leeb BF, Schweitzer H, Montag K, Smolen JS. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis.

J Rheum

2000;27:205-211.

 

Richy F, Bruyere O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensi

ve meta-analysis.

Arch Intern Med

2003;163:1514-1522.

 

McAlindon TE, LaValley MP, Gulin JP, et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assess

ment and meta-analysis.

JAMA

2000;283:1469-1475.

 

Kahan A, Uebelhart D, De Vathaire F, et al. Long term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: The study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial.

Arthritis Rheum

2009;60(2):524-533.

 

Muniyappa R, Karne RJ, Hall G, et al. Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects.

Diabetes

2006;55:3142-3150.

 

Barnhill JG, Fye CL, Williams DW, et al. Chondroitin product selection for the glucosamine/chondroitin arthritis intervention trial.

J Am Pharm Assoc

2006;46:14-24.

 

Au R, Al-Talib TK, Au AY, et al. Avocado soybean unsaponifiables (ASU) suppress TNF- , IL-1 ‚ COX-2, iNOS gene expression, and prostaglandin E2 and nitric oxide production in articular chondrocytes and monocyte/macrophages.

Osteoarthritis Cartilage

2007;15:1249-1255.

THE ORTHOPEDIC SURGEON

AND RHEUMATOLOGIST

#1 RECOMMENDED BRAND

Source: SLACK Incorporated Market Research Survey, June 2005 and February 2006.

Surveys conducted of orthopedic surgeons and rheumatologists relating to glucosamine/chondroitin sulfate brands.